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Table 1
Overall change from admission and transplant to pre-engraftment
Electrolyte N Timepoint Average change to
Pre-Engraftment
SD
(change)
P-value
Phosphorous 244 Admission (A) -0.6836 0.9956 <.001
Transplant (B) -0.4012 1.0076 <.001
Calcium 242 Admission (A) -0.5851 0.7192 <.001
Transplant (B) -0.0971 0.6008 .0126
Potassium 244 Admission (A) -0.2947 0.5642 <.001
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Signiﬁcance and Background: BMT patients are frequently
discharged to outpatient care with a central line catheter in
place. These patients are at increased risk for developing
a central line- associated bloodstream infection (CLABSI). A
review of literature and comparison CLABSI rates showed
a paucity of studies in the outpatient population. An outpa-
tient who develops a CLABSI usually requires admission to
the hospital, where treatment costs may range from
$35,000-53,000. CLABSI surveillance began in January 2009
for our outpatient BMT population utilizing the same NHSN
deﬁnition used for inpatients. An analysis of data collected
over 18 months prompted nursing staff to implement a plan
to target reduction of CLABSIs.
Interventions: BMT Treatment Center nurses were educated
on CLABSI, current rates, and implications for patients as well
as the department. The nurses researched ways to reduce
CLABSIs and developed a post-insertion bundle for central
line care utilizing CDC CLABSI prevention strategies and other
evidence-based practices. Patient education materials were
developed and a post-line insertion patient education plan
was initiated. Nursing compliance with the bundle is
continuallymonitoredby retrospective reviewsof central line
charting,monthly central line audits, and reviewof electronic
patient education tools. CLABSI surveillance is ongoing with
an in-depth review of all CLABSIs for defects in nursing care.
Results: The 18 month pre-bundle CLABSI rate was 1.66 per
1000 patient visits. The 18 month post-bundle rate fell to
0.88 per 1000 patient visits. The actual number of CLABSIs
fell by 30. This resulted in 30 fewer hospital admissions and
a minimal savings of over $1,000,000 dollars to the facility.
Speciﬁcally, the number of coagulase-negative staph infec-
tions, frequently associated with indwelling devices, drop-
ped from 32 pre bundle to 7 post bundle implementation.
Nursing compliance with CLABSI prevention strategies
continues to be well over 90%.Transplant (B) -0.2279 0.5967 <.001TRANSPLANT NURSING-RESEARCH ORAL119
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Background: The rapid hematopoietic cell expansion that
leads to engraftment after SCT requires variety of metabolicand nutritional factors. Hypophosphatemia, has been re-
ported to precede engraftment (Raanani, et al.). Nurses have
noted and we therefore hypothesized that phosphorous,
calcium, and potassium values would drop 2-4 days pre-
engraftment, when compared to either admission for
conditioning (time point A) or day of transplant (time point
B). Being able to predict neutrophil recovery helps nurses be
alert for clinical signs and symptoms of complications such
as cytokine storm/engraftment syndrome, serious infection,
and hyperacute graft versus host disease.
Methods: We retrospectively reviewed records of 244
patients who underwent hematopoietic SCT from January
2005 through May 2006. Electrolyte values were collected at
the time of admission for conditioning (time point A);
transplant day (+/- 1 day; time point B); and 2-4 days prior to
engraftment. Two-sided paired t-tests were conducted
comparing levels for each of the time points A and B
compared to pre-engraftment. For comparison between
groups, two-sided two-sample t-tests were conducted. No
adjustment was made for the multiplicity of testing. Patients
were grouped as follows: overall, by stem cell source
(apheresis, bone marrow, or cord), transplant type (alloge-
neic or autologous), and CD 34 cell dose (>5 or 5 x 106/kg,
for apheresis products only). Patients had their electrolyte
levels measured while in the hospital, and received stan-
dardized electrolyte replacements.
Results: Overall, the values for all the electrolytes two to four
days before engraftment were signiﬁcantly lower than at
time points A or B (P-value range <.001 to .01 e Table 1). We
concluded that drops in electrolyte levels precede neutrophil
engraftment after peripheral blood SCT. Being able to predict
neutrophil engraftment will help nurses be more aware of
possible SCT complications that may occur with
engraftment, and allow the nurses to work with the
medical team to intervene quickly.120
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Myeloablative chemotherapy/radiotherapy prior to
autologous hematopoietic stem cell transplant (AHSCT) is
a leading cause of mucositis associated with signiﬁcant
morbidity. Palifermin has been demonstrated to decrease the
incidence of severe mucositis in adults following total body
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palifermin on the incidence of mucositis in children
following AHSCT has never been studied. In this retrospec-
tive study, we compared the incidence of mucositis and
supportive care required in childrenwho received palifermin
vs. controls (no palifermin) during non-TBI AHSCT. Mucositis
was graded as per WHO criteria. The continuous variables
were summarized by the mean and standard deviation; the
categorical variables were summarized by percentage. The
palifermin vs. control group were compared by two-sided t-
test for continuous measurements and by Chi-square test for
categorical measurements. From 2005-2011, 58 patients
received myeloablative AHSCT, of which n¼25 were in the
palifermin group and n¼33 were in the control group.
Demographic characteristics are presented in Table.
Comparing palifermin vs. the control group: the average time
for neutrophil engraftment was 12.163.21 days vs. 11.5
1.68 (P¼.127), the incidence of grade I and III-IVmucositis
was 80% vs. 90.9%, and 20% (P¼ .02) vs. 42.4% (P¼.07), the
number of days with fever were 4.923.49 vs. 7.094.86
(P¼.063), the number of days patients received PCA were
8.808.39 vs. 8.308.54 (P¼.826), and the number of days
patients were on TPN were 13.5211.32 vs. 11.559.63
(P¼.484), respectively. The incidence of blood stream and
Clostridium difﬁcile infection was 36% vs. 27.3% (P¼.4) and
24% vs. 18.2% (P¼.5), respectively. The average length of
hospital stay 31.447.42 vs. 28.6110.38 (P¼.252) was not
statistically different between the palifermin and control
groups. In summary, we were unable to demonstrate that
there was a statistical difference with incidence of mucositis
and other supportive care needs or a decrease in hospital
stay in the palifermin group. In children receiving AHSCT,
palifermin should only be used in the setting of a large
prospective study.Variable Control group
(No Palifermin,
n¼33) Mean (SD)
Palifermin group
(n¼25)Mean (SD)
P-value
Age 6.85 (5.49) 7.96 (6.19) .473
Gender:
Male 20 (60.6%) 14 (56%) .724
Female 13 (39.4%) 11 (44%)
Weight 30.62 (27.08) 35.02 (25.95) .535
BSA 0.98 (0.55) 1.05 (0.51) .580
Brain Tumor 15 (45.5%) 3 (12%) .024
Solid Tumor 11 (33.3%) 14 (56%)
Lymphoma 7 (21.2%) 8 (32%)
Disease Status .671
CR/PR 29 (87.9%) 21 (84.0%)
SD/PD 4 (16%) 4 (12.1%)
Prior Radiation: .120
Yes 3 (9.1%) 6 (24%)
No 30 (90.9%) 19 (76%)
HSV serostatus: .330
Positive 25 (75.8%) 16 (64%)
Negative 8 (24.2%) 9 (36%)
Creatinine clearance 118.1 (42.55) 134.8 (49.31) .176TRANSPLANT PHARMACY ORAL
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Background: The use of ﬁlgrastimwith or without plerixafor
has been shown to be an effective modality for the mobili-
zation of peripheral blood stem cells. However, questions
remain as to the CD34+ count that would best predict for
efﬁcient collection. We developed a ﬁlgrastim-based mobi-
lization algorithm with a predetermined decision point for
the inclusion of plerixafor and a CD34+ count of 20 cells/uL as
the trigger for collection. The purpose of our evaluation was
to determine the efﬁcacy of this algorithm, as well as the
impact on plerixafor use, in patients undergoing mobiliza-
tion with ﬁlgrastim prior to autologous hematopoietic stem
cell transplant (HSCT).
Methods: Patients received ﬁlgrastim 10 mcg/kg SC once
daily for 4 days. If the day 5 CD34+ count was > 20/ul,
apheresis was started and ﬁlgrastim was continued until the
collection goal was met. If the day 5 CD34+ count was <10,
plerixafor was started, and if the day 5 CD34+ count was 10-
20, ﬁlgrastim was continued for 1 day with plerixafor added
if the day 6 CD34+ count remained <20/uL. Mobilization
efforts were stopped if the blood CD34+ count remained <
10. The CD34+ cell collection goal was 4 x 106 cells/kg, with
a minimum requirement of 2 x 106 to proceed to HSCT.
Results: To date, 21 patients (18 multiple myeloma and 3
other) have been treated. Fifteen of 18 myeloma patients
received prior lenalidomide therapy. Eleven of the 21
patients were successfully mobilized using ﬁlgrastim alone.
Nine patients who had inadequate CD34+ mobilization with
ﬁlgrastim alone responded to the addition of plerixafor.
Patients requiring plerixafor received an average of 1.56
doses. One patient with non-Hodgkin's lymphoma had no
response to ﬁlgrastim and therefore mobilization attempts
were halted. Seventeen of the 21 patients have successfully
proceeded to transplant, with 3 of the remaining 4 expected
to be admitted for HSCT within the next month. Patients
collected in an average of 1.7 apheresis sessions and collected
an average of 5.15 x 106 CD34+ cells/kg.
Conclusion: We demonstrate here a successful and cost-
effective algorithm-based approach to mobilization,
including a predetermined strategy to include plerixafor for
poormobilizers. By using a decision point for the inclusion or
exclusion of plerixafor, we avoided use of the agent in
patients unlikely to need it for successful collection.122
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Background: Chemotherapy plus GCSF has been an effective
modality for the mobilization of peripheral blood stem cells.
However, the optimal drug, dose, and schedule have not
